Global CD30 (TNFRSF8) Antibody Market Research Report 2024, Forecast to 2032
Report Overview
CD30 (TNFRSF8) Antibody is an antibody specific for CD30 protein.
The global CD30 (TNFRSF8) Antibody market size was estimated at USD 394.60 million in 2023 and is projected to reach USD 1129.94 million by 2032, exhibiting a CAGR of 12.40% during the forecast period.
North America CD30 (TNFRSF8) Antibody market size was estimated at USD 125.84 million in 2023, at a CAGR of 10.63% during the forecast period of 2024 through 2032.
This report provides a deep insight into the global CD30 (TNFRSF8) Antibody market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global CD30 (TNFRSF8) Antibody Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the CD30 (TNFRSF8) Antibody market in any manner.
Global CD30 (TNFRSF8) Antibody Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Sino Biological
Inc.
Bio-Techne
Thermo Fisher Scientific (China) Co.
Ltd.
Boster Biological Technology
MyBiosource
Inc.
Abeomics Inc.
Abbexa
Cell Signaling Technology
Inc.
Creative Diagnostics
OriGene Technologies
Inc.
Merck
Cayman Chemical
CUSABIO
Biotium
BioLegend
Abcepta
ProSci Incorporated
Market Segmentation (by Type)
Monoclonal Antibody
Polyclonal Antibody
Market Segmentation (by Application)
Flow Cytometry
ELISA
Western Blot
Immunofluorescence
Others
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the CD30 (TNFRSF8) Antibody Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of CD30 (TNFRSF8) Antibody, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
Chapter 13 is the main points and conclusions of the report.
CD30 (TNFRSF8) Antibody is an antibody specific for CD30 protein.
The global CD30 (TNFRSF8) Antibody market size was estimated at USD 394.60 million in 2023 and is projected to reach USD 1129.94 million by 2032, exhibiting a CAGR of 12.40% during the forecast period.
North America CD30 (TNFRSF8) Antibody market size was estimated at USD 125.84 million in 2023, at a CAGR of 10.63% during the forecast period of 2024 through 2032.
This report provides a deep insight into the global CD30 (TNFRSF8) Antibody market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global CD30 (TNFRSF8) Antibody Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the CD30 (TNFRSF8) Antibody market in any manner.
Global CD30 (TNFRSF8) Antibody Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Sino Biological
Inc.
Bio-Techne
Thermo Fisher Scientific (China) Co.
Ltd.
Boster Biological Technology
MyBiosource
Inc.
Abeomics Inc.
Abbexa
Cell Signaling Technology
Inc.
Creative Diagnostics
OriGene Technologies
Inc.
Merck
Cayman Chemical
CUSABIO
Biotium
BioLegend
Abcepta
ProSci Incorporated
Market Segmentation (by Type)
Monoclonal Antibody
Polyclonal Antibody
Market Segmentation (by Application)
Flow Cytometry
ELISA
Western Blot
Immunofluorescence
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the CD30 (TNFRSF8) Antibody Market
- Overview of the regional outlook of the CD30 (TNFRSF8) Antibody Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the CD30 (TNFRSF8) Antibody Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of CD30 (TNFRSF8) Antibody, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
Chapter 13 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of CD30 (TNFRSF8) Antibody
1.2 Key Market Segments
1.2.1 CD30 (TNFRSF8) Antibody Segment by Type
1.2.2 CD30 (TNFRSF8) Antibody Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 CD30 (TNFRSF8) ANTIBODY MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global CD30 (TNFRSF8) Antibody Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global CD30 (TNFRSF8) Antibody Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 CD30 (TNFRSF8) ANTIBODY MARKET COMPETITIVE LANDSCAPE
3.1 Global CD30 (TNFRSF8) Antibody Sales by Manufacturers (2019-2024)
3.2 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Manufacturers (2019-2024)
3.3 CD30 (TNFRSF8) Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global CD30 (TNFRSF8) Antibody Average Price by Manufacturers (2019-2024)
3.5 Manufacturers CD30 (TNFRSF8) Antibody Sales Sites, Area Served, Product Type
3.6 CD30 (TNFRSF8) Antibody Market Competitive Situation and Trends
3.6.1 CD30 (TNFRSF8) Antibody Market Concentration Rate
3.6.2 Global 5 and 10 Largest CD30 (TNFRSF8) Antibody Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 CD30 (TNFRSF8) ANTIBODY INDUSTRY CHAIN ANALYSIS
4.1 CD30 (TNFRSF8) Antibody Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF CD30 (TNFRSF8) ANTIBODY MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 CD30 (TNFRSF8) ANTIBODY MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2019-2024)
6.3 Global CD30 (TNFRSF8) Antibody Market Size Market Share by Type (2019-2024)
6.4 Global CD30 (TNFRSF8) Antibody Price by Type (2019-2024)
7 CD30 (TNFRSF8) ANTIBODY MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global CD30 (TNFRSF8) Antibody Market Sales by Application (2019-2024)
7.3 Global CD30 (TNFRSF8) Antibody Market Size (M USD) by Application (2019-2024)
7.4 Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2019-2024)
8 CD30 (TNFRSF8) ANTIBODY MARKET CONSUMPTION BY REGION
8.1 Global CD30 (TNFRSF8) Antibody Sales by Region
8.1.1 Global CD30 (TNFRSF8) Antibody Sales by Region
8.1.2 Global CD30 (TNFRSF8) Antibody Sales Market Share by Region
8.2 North America
8.2.1 North America CD30 (TNFRSF8) Antibody Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe CD30 (TNFRSF8) Antibody Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific CD30 (TNFRSF8) Antibody Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America CD30 (TNFRSF8) Antibody Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa CD30 (TNFRSF8) Antibody Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 CD30 (TNFRSF8) ANTIBODY MARKET PRODUCTION BY REGION
9.1 Global Production of CD30 (TNFRSF8) Antibody by Region (2019-2024)
9.2 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Region (2019-2024)
9.3 Global CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2019-2024)
9.4 North America CD30 (TNFRSF8) Antibody Production
9.4.1 North America CD30 (TNFRSF8) Antibody Production Growth Rate (2019-2024)
9.4.2 North America CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2019-2024)
9.5 Europe CD30 (TNFRSF8) Antibody Production
9.5.1 Europe CD30 (TNFRSF8) Antibody Production Growth Rate (2019-2024)
9.5.2 Europe CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2019-2024)
9.6 Japan CD30 (TNFRSF8) Antibody Production (2019-2024)
9.6.1 Japan CD30 (TNFRSF8) Antibody Production Growth Rate (2019-2024)
9.6.2 Japan CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2019-2024)
9.7 China CD30 (TNFRSF8) Antibody Production (2019-2024)
9.7.1 China CD30 (TNFRSF8) Antibody Production Growth Rate (2019-2024)
9.7.2 China CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2019-2024)
10 KEY COMPANIES PROFILE
10.1 Sino Biological
10.1.1 Sino Biological CD30 (TNFRSF8) Antibody Basic Information
10.1.2 Sino Biological CD30 (TNFRSF8) Antibody Product Overview
10.1.3 Sino Biological CD30 (TNFRSF8) Antibody Product Market Performance
10.1.4 Sino Biological Business Overview
10.1.5 Sino Biological CD30 (TNFRSF8) Antibody SWOT Analysis
10.1.6 Sino Biological Recent Developments
10.2 Inc.
10.2.1 Inc. CD30 (TNFRSF8) Antibody Basic Information
10.2.2 Inc. CD30 (TNFRSF8) Antibody Product Overview
10.2.3 Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.2.4 Inc. Business Overview
10.2.5 Inc. CD30 (TNFRSF8) Antibody SWOT Analysis
10.2.6 Inc. Recent Developments
10.3 Bio-Techne
10.3.1 Bio-Techne CD30 (TNFRSF8) Antibody Basic Information
10.3.2 Bio-Techne CD30 (TNFRSF8) Antibody Product Overview
10.3.3 Bio-Techne CD30 (TNFRSF8) Antibody Product Market Performance
10.3.4 Bio-Techne CD30 (TNFRSF8) Antibody SWOT Analysis
10.3.5 Bio-Techne Business Overview
10.3.6 Bio-Techne Recent Developments
10.4 Thermo Fisher Scientific (China) Co.
10.4.1 Thermo Fisher Scientific (China) Co. CD30 (TNFRSF8) Antibody Basic Information
10.4.2 Thermo Fisher Scientific (China) Co. CD30 (TNFRSF8) Antibody Product Overview
10.4.3 Thermo Fisher Scientific (China) Co. CD30 (TNFRSF8) Antibody Product Market Performance
10.4.4 Thermo Fisher Scientific (China) Co. Business Overview
10.4.5 Thermo Fisher Scientific (China) Co. Recent Developments
10.5 Ltd.
10.5.1 Ltd. CD30 (TNFRSF8) Antibody Basic Information
10.5.2 Ltd. CD30 (TNFRSF8) Antibody Product Overview
10.5.3 Ltd. CD30 (TNFRSF8) Antibody Product Market Performance
10.5.4 Ltd. Business Overview
10.5.5 Ltd. Recent Developments
10.6 Boster Biological Technology
10.6.1 Boster Biological Technology CD30 (TNFRSF8) Antibody Basic Information
10.6.2 Boster Biological Technology CD30 (TNFRSF8) Antibody Product Overview
10.6.3 Boster Biological Technology CD30 (TNFRSF8) Antibody Product Market Performance
10.6.4 Boster Biological Technology Business Overview
10.6.5 Boster Biological Technology Recent Developments
10.7 MyBiosource
10.7.1 MyBiosource CD30 (TNFRSF8) Antibody Basic Information
10.7.2 MyBiosource CD30 (TNFRSF8) Antibody Product Overview
10.7.3 MyBiosource CD30 (TNFRSF8) Antibody Product Market Performance
10.7.4 MyBiosource Business Overview
10.7.5 MyBiosource Recent Developments
10.8 Inc.
10.8.1 Inc. CD30 (TNFRSF8) Antibody Basic Information
10.8.2 Inc. CD30 (TNFRSF8) Antibody Product Overview
10.8.3 Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.8.4 Inc. Business Overview
10.8.5 Inc. Recent Developments
10.9 Abeomics Inc.
10.9.1 Abeomics Inc. CD30 (TNFRSF8) Antibody Basic Information
10.9.2 Abeomics Inc. CD30 (TNFRSF8) Antibody Product Overview
10.9.3 Abeomics Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.9.4 Abeomics Inc. Business Overview
10.9.5 Abeomics Inc. Recent Developments
10.10 Abbexa
10.10.1 Abbexa CD30 (TNFRSF8) Antibody Basic Information
10.10.2 Abbexa CD30 (TNFRSF8) Antibody Product Overview
10.10.3 Abbexa CD30 (TNFRSF8) Antibody Product Market Performance
10.10.4 Abbexa Business Overview
10.10.5 Abbexa Recent Developments
10.11 Cell Signaling Technology
10.11.1 Cell Signaling Technology CD30 (TNFRSF8) Antibody Basic Information
10.11.2 Cell Signaling Technology CD30 (TNFRSF8) Antibody Product Overview
10.11.3 Cell Signaling Technology CD30 (TNFRSF8) Antibody Product Market Performance
10.11.4 Cell Signaling Technology Business Overview
10.11.5 Cell Signaling Technology Recent Developments
10.12 Inc.
10.12.1 Inc. CD30 (TNFRSF8) Antibody Basic Information
10.12.2 Inc. CD30 (TNFRSF8) Antibody Product Overview
10.12.3 Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.12.4 Inc. Business Overview
10.12.5 Inc. Recent Developments
10.13 Creative Diagnostics
10.13.1 Creative Diagnostics CD30 (TNFRSF8) Antibody Basic Information
10.13.2 Creative Diagnostics CD30 (TNFRSF8) Antibody Product Overview
10.13.3 Creative Diagnostics CD30 (TNFRSF8) Antibody Product Market Performance
10.13.4 Creative Diagnostics Business Overview
10.13.5 Creative Diagnostics Recent Developments
10.14 OriGene Technologies
10.14.1 OriGene Technologies CD30 (TNFRSF8) Antibody Basic Information
10.14.2 OriGene Technologies CD30 (TNFRSF8) Antibody Product Overview
10.14.3 OriGene Technologies CD30 (TNFRSF8) Antibody Product Market Performance
10.14.4 OriGene Technologies Business Overview
10.14.5 OriGene Technologies Recent Developments
10.15 Inc.
10.15.1 Inc. CD30 (TNFRSF8) Antibody Basic Information
10.15.2 Inc. CD30 (TNFRSF8) Antibody Product Overview
10.15.3 Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.15.4 Inc. Business Overview
10.15.5 Inc. Recent Developments
10.16 Merck
10.16.1 Merck CD30 (TNFRSF8) Antibody Basic Information
10.16.2 Merck CD30 (TNFRSF8) Antibody Product Overview
10.16.3 Merck CD30 (TNFRSF8) Antibody Product Market Performance
10.16.4 Merck Business Overview
10.16.5 Merck Recent Developments
10.17 Cayman Chemical
10.17.1 Cayman Chemical CD30 (TNFRSF8) Antibody Basic Information
10.17.2 Cayman Chemical CD30 (TNFRSF8) Antibody Product Overview
10.17.3 Cayman Chemical CD30 (TNFRSF8) Antibody Product Market Performance
10.17.4 Cayman Chemical Business Overview
10.17.5 Cayman Chemical Recent Developments
10.18 CUSABIO
10.18.1 CUSABIO CD30 (TNFRSF8) Antibody Basic Information
10.18.2 CUSABIO CD30 (TNFRSF8) Antibody Product Overview
10.18.3 CUSABIO CD30 (TNFRSF8) Antibody Product Market Performance
10.18.4 CUSABIO Business Overview
10.18.5 CUSABIO Recent Developments
10.19 Biotium
10.19.1 Biotium CD30 (TNFRSF8) Antibody Basic Information
10.19.2 Biotium CD30 (TNFRSF8) Antibody Product Overview
10.19.3 Biotium CD30 (TNFRSF8) Antibody Product Market Performance
10.19.4 Biotium Business Overview
10.19.5 Biotium Recent Developments
10.20 BioLegend
10.20.1 BioLegend CD30 (TNFRSF8) Antibody Basic Information
10.20.2 BioLegend CD30 (TNFRSF8) Antibody Product Overview
10.20.3 BioLegend CD30 (TNFRSF8) Antibody Product Market Performance
10.20.4 BioLegend Business Overview
10.20.5 BioLegend Recent Developments
10.21 Abcepta
10.21.1 Abcepta CD30 (TNFRSF8) Antibody Basic Information
10.21.2 Abcepta CD30 (TNFRSF8) Antibody Product Overview
10.21.3 Abcepta CD30 (TNFRSF8) Antibody Product Market Performance
10.21.4 Abcepta Business Overview
10.21.5 Abcepta Recent Developments
10.22 ProSci Incorporated
10.22.1 ProSci Incorporated CD30 (TNFRSF8) Antibody Basic Information
10.22.2 ProSci Incorporated CD30 (TNFRSF8) Antibody Product Overview
10.22.3 ProSci Incorporated CD30 (TNFRSF8) Antibody Product Market Performance
10.22.4 ProSci Incorporated Business Overview
10.22.5 ProSci Incorporated Recent Developments
11 CD30 (TNFRSF8) ANTIBODY MARKET FORECAST BY REGION
11.1 Global CD30 (TNFRSF8) Antibody Market Size Forecast
11.2 Global CD30 (TNFRSF8) Antibody Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe CD30 (TNFRSF8) Antibody Market Size Forecast by Country
11.2.3 Asia Pacific CD30 (TNFRSF8) Antibody Market Size Forecast by Region
11.2.4 South America CD30 (TNFRSF8) Antibody Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of CD30 (TNFRSF8) Antibody by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)
12.1 Global CD30 (TNFRSF8) Antibody Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of CD30 (TNFRSF8) Antibody by Type (2025-2032)
12.1.2 Global CD30 (TNFRSF8) Antibody Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of CD30 (TNFRSF8) Antibody by Type (2025-2032)
12.2 Global CD30 (TNFRSF8) Antibody Market Forecast by Application (2025-2032)
12.2.1 Global CD30 (TNFRSF8) Antibody Sales (K MT) Forecast by Application
12.2.2 Global CD30 (TNFRSF8) Antibody Market Size (M USD) Forecast by Application (2025-2032)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of CD30 (TNFRSF8) Antibody
1.2 Key Market Segments
1.2.1 CD30 (TNFRSF8) Antibody Segment by Type
1.2.2 CD30 (TNFRSF8) Antibody Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 CD30 (TNFRSF8) ANTIBODY MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global CD30 (TNFRSF8) Antibody Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global CD30 (TNFRSF8) Antibody Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 CD30 (TNFRSF8) ANTIBODY MARKET COMPETITIVE LANDSCAPE
3.1 Global CD30 (TNFRSF8) Antibody Sales by Manufacturers (2019-2024)
3.2 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Manufacturers (2019-2024)
3.3 CD30 (TNFRSF8) Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global CD30 (TNFRSF8) Antibody Average Price by Manufacturers (2019-2024)
3.5 Manufacturers CD30 (TNFRSF8) Antibody Sales Sites, Area Served, Product Type
3.6 CD30 (TNFRSF8) Antibody Market Competitive Situation and Trends
3.6.1 CD30 (TNFRSF8) Antibody Market Concentration Rate
3.6.2 Global 5 and 10 Largest CD30 (TNFRSF8) Antibody Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 CD30 (TNFRSF8) ANTIBODY INDUSTRY CHAIN ANALYSIS
4.1 CD30 (TNFRSF8) Antibody Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF CD30 (TNFRSF8) ANTIBODY MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 CD30 (TNFRSF8) ANTIBODY MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2019-2024)
6.3 Global CD30 (TNFRSF8) Antibody Market Size Market Share by Type (2019-2024)
6.4 Global CD30 (TNFRSF8) Antibody Price by Type (2019-2024)
7 CD30 (TNFRSF8) ANTIBODY MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global CD30 (TNFRSF8) Antibody Market Sales by Application (2019-2024)
7.3 Global CD30 (TNFRSF8) Antibody Market Size (M USD) by Application (2019-2024)
7.4 Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2019-2024)
8 CD30 (TNFRSF8) ANTIBODY MARKET CONSUMPTION BY REGION
8.1 Global CD30 (TNFRSF8) Antibody Sales by Region
8.1.1 Global CD30 (TNFRSF8) Antibody Sales by Region
8.1.2 Global CD30 (TNFRSF8) Antibody Sales Market Share by Region
8.2 North America
8.2.1 North America CD30 (TNFRSF8) Antibody Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe CD30 (TNFRSF8) Antibody Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific CD30 (TNFRSF8) Antibody Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America CD30 (TNFRSF8) Antibody Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa CD30 (TNFRSF8) Antibody Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 CD30 (TNFRSF8) ANTIBODY MARKET PRODUCTION BY REGION
9.1 Global Production of CD30 (TNFRSF8) Antibody by Region (2019-2024)
9.2 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Region (2019-2024)
9.3 Global CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2019-2024)
9.4 North America CD30 (TNFRSF8) Antibody Production
9.4.1 North America CD30 (TNFRSF8) Antibody Production Growth Rate (2019-2024)
9.4.2 North America CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2019-2024)
9.5 Europe CD30 (TNFRSF8) Antibody Production
9.5.1 Europe CD30 (TNFRSF8) Antibody Production Growth Rate (2019-2024)
9.5.2 Europe CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2019-2024)
9.6 Japan CD30 (TNFRSF8) Antibody Production (2019-2024)
9.6.1 Japan CD30 (TNFRSF8) Antibody Production Growth Rate (2019-2024)
9.6.2 Japan CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2019-2024)
9.7 China CD30 (TNFRSF8) Antibody Production (2019-2024)
9.7.1 China CD30 (TNFRSF8) Antibody Production Growth Rate (2019-2024)
9.7.2 China CD30 (TNFRSF8) Antibody Production, Revenue, Price and Gross Margin (2019-2024)
10 KEY COMPANIES PROFILE
10.1 Sino Biological
10.1.1 Sino Biological CD30 (TNFRSF8) Antibody Basic Information
10.1.2 Sino Biological CD30 (TNFRSF8) Antibody Product Overview
10.1.3 Sino Biological CD30 (TNFRSF8) Antibody Product Market Performance
10.1.4 Sino Biological Business Overview
10.1.5 Sino Biological CD30 (TNFRSF8) Antibody SWOT Analysis
10.1.6 Sino Biological Recent Developments
10.2 Inc.
10.2.1 Inc. CD30 (TNFRSF8) Antibody Basic Information
10.2.2 Inc. CD30 (TNFRSF8) Antibody Product Overview
10.2.3 Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.2.4 Inc. Business Overview
10.2.5 Inc. CD30 (TNFRSF8) Antibody SWOT Analysis
10.2.6 Inc. Recent Developments
10.3 Bio-Techne
10.3.1 Bio-Techne CD30 (TNFRSF8) Antibody Basic Information
10.3.2 Bio-Techne CD30 (TNFRSF8) Antibody Product Overview
10.3.3 Bio-Techne CD30 (TNFRSF8) Antibody Product Market Performance
10.3.4 Bio-Techne CD30 (TNFRSF8) Antibody SWOT Analysis
10.3.5 Bio-Techne Business Overview
10.3.6 Bio-Techne Recent Developments
10.4 Thermo Fisher Scientific (China) Co.
10.4.1 Thermo Fisher Scientific (China) Co. CD30 (TNFRSF8) Antibody Basic Information
10.4.2 Thermo Fisher Scientific (China) Co. CD30 (TNFRSF8) Antibody Product Overview
10.4.3 Thermo Fisher Scientific (China) Co. CD30 (TNFRSF8) Antibody Product Market Performance
10.4.4 Thermo Fisher Scientific (China) Co. Business Overview
10.4.5 Thermo Fisher Scientific (China) Co. Recent Developments
10.5 Ltd.
10.5.1 Ltd. CD30 (TNFRSF8) Antibody Basic Information
10.5.2 Ltd. CD30 (TNFRSF8) Antibody Product Overview
10.5.3 Ltd. CD30 (TNFRSF8) Antibody Product Market Performance
10.5.4 Ltd. Business Overview
10.5.5 Ltd. Recent Developments
10.6 Boster Biological Technology
10.6.1 Boster Biological Technology CD30 (TNFRSF8) Antibody Basic Information
10.6.2 Boster Biological Technology CD30 (TNFRSF8) Antibody Product Overview
10.6.3 Boster Biological Technology CD30 (TNFRSF8) Antibody Product Market Performance
10.6.4 Boster Biological Technology Business Overview
10.6.5 Boster Biological Technology Recent Developments
10.7 MyBiosource
10.7.1 MyBiosource CD30 (TNFRSF8) Antibody Basic Information
10.7.2 MyBiosource CD30 (TNFRSF8) Antibody Product Overview
10.7.3 MyBiosource CD30 (TNFRSF8) Antibody Product Market Performance
10.7.4 MyBiosource Business Overview
10.7.5 MyBiosource Recent Developments
10.8 Inc.
10.8.1 Inc. CD30 (TNFRSF8) Antibody Basic Information
10.8.2 Inc. CD30 (TNFRSF8) Antibody Product Overview
10.8.3 Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.8.4 Inc. Business Overview
10.8.5 Inc. Recent Developments
10.9 Abeomics Inc.
10.9.1 Abeomics Inc. CD30 (TNFRSF8) Antibody Basic Information
10.9.2 Abeomics Inc. CD30 (TNFRSF8) Antibody Product Overview
10.9.3 Abeomics Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.9.4 Abeomics Inc. Business Overview
10.9.5 Abeomics Inc. Recent Developments
10.10 Abbexa
10.10.1 Abbexa CD30 (TNFRSF8) Antibody Basic Information
10.10.2 Abbexa CD30 (TNFRSF8) Antibody Product Overview
10.10.3 Abbexa CD30 (TNFRSF8) Antibody Product Market Performance
10.10.4 Abbexa Business Overview
10.10.5 Abbexa Recent Developments
10.11 Cell Signaling Technology
10.11.1 Cell Signaling Technology CD30 (TNFRSF8) Antibody Basic Information
10.11.2 Cell Signaling Technology CD30 (TNFRSF8) Antibody Product Overview
10.11.3 Cell Signaling Technology CD30 (TNFRSF8) Antibody Product Market Performance
10.11.4 Cell Signaling Technology Business Overview
10.11.5 Cell Signaling Technology Recent Developments
10.12 Inc.
10.12.1 Inc. CD30 (TNFRSF8) Antibody Basic Information
10.12.2 Inc. CD30 (TNFRSF8) Antibody Product Overview
10.12.3 Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.12.4 Inc. Business Overview
10.12.5 Inc. Recent Developments
10.13 Creative Diagnostics
10.13.1 Creative Diagnostics CD30 (TNFRSF8) Antibody Basic Information
10.13.2 Creative Diagnostics CD30 (TNFRSF8) Antibody Product Overview
10.13.3 Creative Diagnostics CD30 (TNFRSF8) Antibody Product Market Performance
10.13.4 Creative Diagnostics Business Overview
10.13.5 Creative Diagnostics Recent Developments
10.14 OriGene Technologies
10.14.1 OriGene Technologies CD30 (TNFRSF8) Antibody Basic Information
10.14.2 OriGene Technologies CD30 (TNFRSF8) Antibody Product Overview
10.14.3 OriGene Technologies CD30 (TNFRSF8) Antibody Product Market Performance
10.14.4 OriGene Technologies Business Overview
10.14.5 OriGene Technologies Recent Developments
10.15 Inc.
10.15.1 Inc. CD30 (TNFRSF8) Antibody Basic Information
10.15.2 Inc. CD30 (TNFRSF8) Antibody Product Overview
10.15.3 Inc. CD30 (TNFRSF8) Antibody Product Market Performance
10.15.4 Inc. Business Overview
10.15.5 Inc. Recent Developments
10.16 Merck
10.16.1 Merck CD30 (TNFRSF8) Antibody Basic Information
10.16.2 Merck CD30 (TNFRSF8) Antibody Product Overview
10.16.3 Merck CD30 (TNFRSF8) Antibody Product Market Performance
10.16.4 Merck Business Overview
10.16.5 Merck Recent Developments
10.17 Cayman Chemical
10.17.1 Cayman Chemical CD30 (TNFRSF8) Antibody Basic Information
10.17.2 Cayman Chemical CD30 (TNFRSF8) Antibody Product Overview
10.17.3 Cayman Chemical CD30 (TNFRSF8) Antibody Product Market Performance
10.17.4 Cayman Chemical Business Overview
10.17.5 Cayman Chemical Recent Developments
10.18 CUSABIO
10.18.1 CUSABIO CD30 (TNFRSF8) Antibody Basic Information
10.18.2 CUSABIO CD30 (TNFRSF8) Antibody Product Overview
10.18.3 CUSABIO CD30 (TNFRSF8) Antibody Product Market Performance
10.18.4 CUSABIO Business Overview
10.18.5 CUSABIO Recent Developments
10.19 Biotium
10.19.1 Biotium CD30 (TNFRSF8) Antibody Basic Information
10.19.2 Biotium CD30 (TNFRSF8) Antibody Product Overview
10.19.3 Biotium CD30 (TNFRSF8) Antibody Product Market Performance
10.19.4 Biotium Business Overview
10.19.5 Biotium Recent Developments
10.20 BioLegend
10.20.1 BioLegend CD30 (TNFRSF8) Antibody Basic Information
10.20.2 BioLegend CD30 (TNFRSF8) Antibody Product Overview
10.20.3 BioLegend CD30 (TNFRSF8) Antibody Product Market Performance
10.20.4 BioLegend Business Overview
10.20.5 BioLegend Recent Developments
10.21 Abcepta
10.21.1 Abcepta CD30 (TNFRSF8) Antibody Basic Information
10.21.2 Abcepta CD30 (TNFRSF8) Antibody Product Overview
10.21.3 Abcepta CD30 (TNFRSF8) Antibody Product Market Performance
10.21.4 Abcepta Business Overview
10.21.5 Abcepta Recent Developments
10.22 ProSci Incorporated
10.22.1 ProSci Incorporated CD30 (TNFRSF8) Antibody Basic Information
10.22.2 ProSci Incorporated CD30 (TNFRSF8) Antibody Product Overview
10.22.3 ProSci Incorporated CD30 (TNFRSF8) Antibody Product Market Performance
10.22.4 ProSci Incorporated Business Overview
10.22.5 ProSci Incorporated Recent Developments
11 CD30 (TNFRSF8) ANTIBODY MARKET FORECAST BY REGION
11.1 Global CD30 (TNFRSF8) Antibody Market Size Forecast
11.2 Global CD30 (TNFRSF8) Antibody Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe CD30 (TNFRSF8) Antibody Market Size Forecast by Country
11.2.3 Asia Pacific CD30 (TNFRSF8) Antibody Market Size Forecast by Region
11.2.4 South America CD30 (TNFRSF8) Antibody Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of CD30 (TNFRSF8) Antibody by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)
12.1 Global CD30 (TNFRSF8) Antibody Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of CD30 (TNFRSF8) Antibody by Type (2025-2032)
12.1.2 Global CD30 (TNFRSF8) Antibody Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of CD30 (TNFRSF8) Antibody by Type (2025-2032)
12.2 Global CD30 (TNFRSF8) Antibody Market Forecast by Application (2025-2032)
12.2.1 Global CD30 (TNFRSF8) Antibody Sales (K MT) Forecast by Application
12.2.2 Global CD30 (TNFRSF8) Antibody Market Size (M USD) Forecast by Application (2025-2032)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. CD30 (TNFRSF8) Antibody Market Size Comparison by Region (M USD)
Table 5. Global CD30 (TNFRSF8) Antibody Sales (K MT) by Manufacturers (2019-2024)
Table 6. Global CD30 (TNFRSF8) Antibody Sales Market Share by Manufacturers (2019-2024)
Table 7. Global CD30 (TNFRSF8) Antibody Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global CD30 (TNFRSF8) Antibody Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD30 (TNFRSF8) Antibody as of 2022)
Table 10. Global Market CD30 (TNFRSF8) Antibody Average Price (USD/MT) of Key Manufacturers (2019-2024)
Table 11. Manufacturers CD30 (TNFRSF8) Antibody Sales Sites and Area Served
Table 12. Manufacturers CD30 (TNFRSF8) Antibody Product Type
Table 13. Global CD30 (TNFRSF8) Antibody Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of CD30 (TNFRSF8) Antibody
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. CD30 (TNFRSF8) Antibody Market Challenges
Table 22. Global CD30 (TNFRSF8) Antibody Sales by Type (K MT)
Table 23. Global CD30 (TNFRSF8) Antibody Market Size by Type (M USD)
Table 24. Global CD30 (TNFRSF8) Antibody Sales (K MT) by Type (2019-2024)
Table 25. Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2019-2024)
Table 26. Global CD30 (TNFRSF8) Antibody Market Size (M USD) by Type (2019-2024)
Table 27. Global CD30 (TNFRSF8) Antibody Market Size Share by Type (2019-2024)
Table 28. Global CD30 (TNFRSF8) Antibody Price (USD/MT) by Type (2019-2024)
Table 29. Global CD30 (TNFRSF8) Antibody Sales (K MT) by Application
Table 30. Global CD30 (TNFRSF8) Antibody Market Size by Application
Table 31. Global CD30 (TNFRSF8) Antibody Sales by Application (2019-2024) & (K MT)
Table 32. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2019-2024)
Table 33. Global CD30 (TNFRSF8) Antibody Sales by Application (2019-2024) & (M USD)
Table 34. Global CD30 (TNFRSF8) Antibody Market Share by Application (2019-2024)
Table 35. Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2019-2024)
Table 36. Global CD30 (TNFRSF8) Antibody Sales by Region (2019-2024) & (K MT)
Table 37. Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2019-2024)
Table 38. North America CD30 (TNFRSF8) Antibody Sales by Country (2019-2024) & (K MT)
Table 39. Europe CD30 (TNFRSF8) Antibody Sales by Country (2019-2024) & (K MT)
Table 40. Asia Pacific CD30 (TNFRSF8) Antibody Sales by Region (2019-2024) & (K MT)
Table 41. South America CD30 (TNFRSF8) Antibody Sales by Country (2019-2024) & (K MT)
Table 42. Middle East and Africa CD30 (TNFRSF8) Antibody Sales by Region (2019-2024) & (K MT)
Table 43. Global CD30 (TNFRSF8) Antibody Production (K MT) by Region (2019-2024)
Table 44. Global CD30 (TNFRSF8) Antibody Revenue (US$ Million) by Region (2019-2024)
Table 45. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Region (2019-2024)
Table 46. Global CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 47. North America CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 48. Europe CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 49. Japan CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 50. China CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 51. Sino Biological CD30 (TNFRSF8) Antibody Basic Information
Table 52. Sino Biological CD30 (TNFRSF8) Antibody Product Overview
Table 53. Sino Biological CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 54. Sino Biological Business Overview
Table 55. Sino Biological CD30 (TNFRSF8) Antibody SWOT Analysis
Table 56. Sino Biological Recent Developments
Table 57. Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 58. Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 59. Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 60. Inc. Business Overview
Table 61. Inc. CD30 (TNFRSF8) Antibody SWOT Analysis
Table 62. Inc. Recent Developments
Table 63. Bio-Techne CD30 (TNFRSF8) Antibody Basic Information
Table 64. Bio-Techne CD30 (TNFRSF8) Antibody Product Overview
Table 65. Bio-Techne CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 66. Bio-Techne CD30 (TNFRSF8) Antibody SWOT Analysis
Table 67. Bio-Techne Business Overview
Table 68. Bio-Techne Recent Developments
Table 69. Thermo Fisher Scientific (China) Co. CD30 (TNFRSF8) Antibody Basic Information
Table 70. Thermo Fisher Scientific (China) Co. CD30 (TNFRSF8) Antibody Product Overview
Table 71. Thermo Fisher Scientific (China) Co. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 72. Thermo Fisher Scientific (China) Co. Business Overview
Table 73. Thermo Fisher Scientific (China) Co. Recent Developments
Table 74. Ltd. CD30 (TNFRSF8) Antibody Basic Information
Table 75. Ltd. CD30 (TNFRSF8) Antibody Product Overview
Table 76. Ltd. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 77. Ltd. Business Overview
Table 78. Ltd. Recent Developments
Table 79. Boster Biological Technology CD30 (TNFRSF8) Antibody Basic Information
Table 80. Boster Biological Technology CD30 (TNFRSF8) Antibody Product Overview
Table 81. Boster Biological Technology CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 82. Boster Biological Technology Business Overview
Table 83. Boster Biological Technology Recent Developments
Table 84. MyBiosource CD30 (TNFRSF8) Antibody Basic Information
Table 85. MyBiosource CD30 (TNFRSF8) Antibody Product Overview
Table 86. MyBiosource CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 87. MyBiosource Business Overview
Table 88. MyBiosource Recent Developments
Table 89. Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 90. Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 91. Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 92. Inc. Business Overview
Table 93. Inc. Recent Developments
Table 94. Abeomics Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 95. Abeomics Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 96. Abeomics Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 97. Abeomics Inc. Business Overview
Table 98. Abeomics Inc. Recent Developments
Table 99. Abbexa CD30 (TNFRSF8) Antibody Basic Information
Table 100. Abbexa CD30 (TNFRSF8) Antibody Product Overview
Table 101. Abbexa CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 102. Abbexa Business Overview
Table 103. Abbexa Recent Developments
Table 104. Cell Signaling Technology CD30 (TNFRSF8) Antibody Basic Information
Table 105. Cell Signaling Technology CD30 (TNFRSF8) Antibody Product Overview
Table 106. Cell Signaling Technology CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 107. Cell Signaling Technology Business Overview
Table 108. Cell Signaling Technology Recent Developments
Table 109. Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 110. Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 111. Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 112. Inc. Business Overview
Table 113. Inc. Recent Developments
Table 114. Creative Diagnostics CD30 (TNFRSF8) Antibody Basic Information
Table 115. Creative Diagnostics CD30 (TNFRSF8) Antibody Product Overview
Table 116. Creative Diagnostics CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 117. Creative Diagnostics Business Overview
Table 118. Creative Diagnostics Recent Developments
Table 119. OriGene Technologies CD30 (TNFRSF8) Antibody Basic Information
Table 120. OriGene Technologies CD30 (TNFRSF8) Antibody Product Overview
Table 121. OriGene Technologies CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 122. OriGene Technologies Business Overview
Table 123. OriGene Technologies Recent Developments
Table 124. Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 125. Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 126. Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 127. Inc. Business Overview
Table 128. Inc. Recent Developments
Table 129. Merck CD30 (TNFRSF8) Antibody Basic Information
Table 130. Merck CD30 (TNFRSF8) Antibody Product Overview
Table 131. Merck CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 132. Merck Business Overview
Table 133. Merck Recent Developments
Table 134. Cayman Chemical CD30 (TNFRSF8) Antibody Basic Information
Table 135. Cayman Chemical CD30 (TNFRSF8) Antibody Product Overview
Table 136. Cayman Chemical CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 137. Cayman Chemical Business Overview
Table 138. Cayman Chemical Recent Developments
Table 139. CUSABIO CD30 (TNFRSF8) Antibody Basic Information
Table 140. CUSABIO CD30 (TNFRSF8) Antibody Product Overview
Table 141. CUSABIO CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 142. CUSABIO Business Overview
Table 143. CUSABIO Recent Developments
Table 144. Biotium CD30 (TNFRSF8) Antibody Basic Information
Table 145. Biotium CD30 (TNFRSF8) Antibody Product Overview
Table 146. Biotium CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 147. Biotium Business Overview
Table 148. Biotium Recent Developments
Table 149. BioLegend CD30 (TNFRSF8) Antibody Basic Information
Table 150. BioLegend CD30 (TNFRSF8) Antibody Product Overview
Table 151. BioLegend CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 152. BioLegend Business Overview
Table 153. BioLegend Recent Developments
Table 154. Abcepta CD30 (TNFRSF8) Antibody Basic Information
Table 155. Abcepta CD30 (TNFRSF8) Antibody Product Overview
Table 156. Abcepta CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 157. Abcepta Business Overview
Table 158. Abcepta Recent Developments
Table 159. ProSci Incorporated CD30 (TNFRSF8) Antibody Basic Information
Table 160. ProSci Incorporated CD30 (TNFRSF8) Antibody Product Overview
Table 161. ProSci Incorporated CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 162. ProSci Incorporated Business Overview
Table 163. ProSci Incorporated Recent Developments
Table 164. Global CD30 (TNFRSF8) Antibody Sales Forecast by Region (2025-2032) & (K MT)
Table 165. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Region (2025-2032) & (M USD)
Table 166. North America CD30 (TNFRSF8) Antibody Sales Forecast by Country (2025-2032) & (K MT)
Table 167. North America CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2025-2032) & (M USD)
Table 168. Europe CD30 (TNFRSF8) Antibody Sales Forecast by Country (2025-2032) & (K MT)
Table 169. Europe CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2025-2032) & (M USD)
Table 170. Asia Pacific CD30 (TNFRSF8) Antibody Sales Forecast by Region (2025-2032) & (K MT)
Table 171. Asia Pacific CD30 (TNFRSF8) Antibody Market Size Forecast by Region (2025-2032) & (M USD)
Table 172. South America CD30 (TNFRSF8) Antibody Sales Forecast by Country (2025-2032) & (K MT)
Table 173. South America CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2025-2032) & (M USD)
Table 174. Middle East and Africa CD30 (TNFRSF8) Antibody Consumption Forecast by Country (2025-2032) & (Units)
Table 175. Middle East and Africa CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2025-2032) & (M USD)
Table 176. Global CD30 (TNFRSF8) Antibody Sales Forecast by Type (2025-2032) & (K MT)
Table 177. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Type (2025-2032) & (M USD)
Table 178. Global CD30 (TNFRSF8) Antibody Price Forecast by Type (2025-2032) & (USD/MT)
Table 179. Global CD30 (TNFRSF8) Antibody Sales (K MT) Forecast by Application (2025-2032)
Table 180. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Application (2025-2032) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. CD30 (TNFRSF8) Antibody Market Size Comparison by Region (M USD)
Table 5. Global CD30 (TNFRSF8) Antibody Sales (K MT) by Manufacturers (2019-2024)
Table 6. Global CD30 (TNFRSF8) Antibody Sales Market Share by Manufacturers (2019-2024)
Table 7. Global CD30 (TNFRSF8) Antibody Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global CD30 (TNFRSF8) Antibody Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD30 (TNFRSF8) Antibody as of 2022)
Table 10. Global Market CD30 (TNFRSF8) Antibody Average Price (USD/MT) of Key Manufacturers (2019-2024)
Table 11. Manufacturers CD30 (TNFRSF8) Antibody Sales Sites and Area Served
Table 12. Manufacturers CD30 (TNFRSF8) Antibody Product Type
Table 13. Global CD30 (TNFRSF8) Antibody Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of CD30 (TNFRSF8) Antibody
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. CD30 (TNFRSF8) Antibody Market Challenges
Table 22. Global CD30 (TNFRSF8) Antibody Sales by Type (K MT)
Table 23. Global CD30 (TNFRSF8) Antibody Market Size by Type (M USD)
Table 24. Global CD30 (TNFRSF8) Antibody Sales (K MT) by Type (2019-2024)
Table 25. Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2019-2024)
Table 26. Global CD30 (TNFRSF8) Antibody Market Size (M USD) by Type (2019-2024)
Table 27. Global CD30 (TNFRSF8) Antibody Market Size Share by Type (2019-2024)
Table 28. Global CD30 (TNFRSF8) Antibody Price (USD/MT) by Type (2019-2024)
Table 29. Global CD30 (TNFRSF8) Antibody Sales (K MT) by Application
Table 30. Global CD30 (TNFRSF8) Antibody Market Size by Application
Table 31. Global CD30 (TNFRSF8) Antibody Sales by Application (2019-2024) & (K MT)
Table 32. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2019-2024)
Table 33. Global CD30 (TNFRSF8) Antibody Sales by Application (2019-2024) & (M USD)
Table 34. Global CD30 (TNFRSF8) Antibody Market Share by Application (2019-2024)
Table 35. Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2019-2024)
Table 36. Global CD30 (TNFRSF8) Antibody Sales by Region (2019-2024) & (K MT)
Table 37. Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2019-2024)
Table 38. North America CD30 (TNFRSF8) Antibody Sales by Country (2019-2024) & (K MT)
Table 39. Europe CD30 (TNFRSF8) Antibody Sales by Country (2019-2024) & (K MT)
Table 40. Asia Pacific CD30 (TNFRSF8) Antibody Sales by Region (2019-2024) & (K MT)
Table 41. South America CD30 (TNFRSF8) Antibody Sales by Country (2019-2024) & (K MT)
Table 42. Middle East and Africa CD30 (TNFRSF8) Antibody Sales by Region (2019-2024) & (K MT)
Table 43. Global CD30 (TNFRSF8) Antibody Production (K MT) by Region (2019-2024)
Table 44. Global CD30 (TNFRSF8) Antibody Revenue (US$ Million) by Region (2019-2024)
Table 45. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Region (2019-2024)
Table 46. Global CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 47. North America CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 48. Europe CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 49. Japan CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 50. China CD30 (TNFRSF8) Antibody Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 51. Sino Biological CD30 (TNFRSF8) Antibody Basic Information
Table 52. Sino Biological CD30 (TNFRSF8) Antibody Product Overview
Table 53. Sino Biological CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 54. Sino Biological Business Overview
Table 55. Sino Biological CD30 (TNFRSF8) Antibody SWOT Analysis
Table 56. Sino Biological Recent Developments
Table 57. Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 58. Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 59. Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 60. Inc. Business Overview
Table 61. Inc. CD30 (TNFRSF8) Antibody SWOT Analysis
Table 62. Inc. Recent Developments
Table 63. Bio-Techne CD30 (TNFRSF8) Antibody Basic Information
Table 64. Bio-Techne CD30 (TNFRSF8) Antibody Product Overview
Table 65. Bio-Techne CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 66. Bio-Techne CD30 (TNFRSF8) Antibody SWOT Analysis
Table 67. Bio-Techne Business Overview
Table 68. Bio-Techne Recent Developments
Table 69. Thermo Fisher Scientific (China) Co. CD30 (TNFRSF8) Antibody Basic Information
Table 70. Thermo Fisher Scientific (China) Co. CD30 (TNFRSF8) Antibody Product Overview
Table 71. Thermo Fisher Scientific (China) Co. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 72. Thermo Fisher Scientific (China) Co. Business Overview
Table 73. Thermo Fisher Scientific (China) Co. Recent Developments
Table 74. Ltd. CD30 (TNFRSF8) Antibody Basic Information
Table 75. Ltd. CD30 (TNFRSF8) Antibody Product Overview
Table 76. Ltd. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 77. Ltd. Business Overview
Table 78. Ltd. Recent Developments
Table 79. Boster Biological Technology CD30 (TNFRSF8) Antibody Basic Information
Table 80. Boster Biological Technology CD30 (TNFRSF8) Antibody Product Overview
Table 81. Boster Biological Technology CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 82. Boster Biological Technology Business Overview
Table 83. Boster Biological Technology Recent Developments
Table 84. MyBiosource CD30 (TNFRSF8) Antibody Basic Information
Table 85. MyBiosource CD30 (TNFRSF8) Antibody Product Overview
Table 86. MyBiosource CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 87. MyBiosource Business Overview
Table 88. MyBiosource Recent Developments
Table 89. Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 90. Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 91. Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 92. Inc. Business Overview
Table 93. Inc. Recent Developments
Table 94. Abeomics Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 95. Abeomics Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 96. Abeomics Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 97. Abeomics Inc. Business Overview
Table 98. Abeomics Inc. Recent Developments
Table 99. Abbexa CD30 (TNFRSF8) Antibody Basic Information
Table 100. Abbexa CD30 (TNFRSF8) Antibody Product Overview
Table 101. Abbexa CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 102. Abbexa Business Overview
Table 103. Abbexa Recent Developments
Table 104. Cell Signaling Technology CD30 (TNFRSF8) Antibody Basic Information
Table 105. Cell Signaling Technology CD30 (TNFRSF8) Antibody Product Overview
Table 106. Cell Signaling Technology CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 107. Cell Signaling Technology Business Overview
Table 108. Cell Signaling Technology Recent Developments
Table 109. Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 110. Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 111. Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 112. Inc. Business Overview
Table 113. Inc. Recent Developments
Table 114. Creative Diagnostics CD30 (TNFRSF8) Antibody Basic Information
Table 115. Creative Diagnostics CD30 (TNFRSF8) Antibody Product Overview
Table 116. Creative Diagnostics CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 117. Creative Diagnostics Business Overview
Table 118. Creative Diagnostics Recent Developments
Table 119. OriGene Technologies CD30 (TNFRSF8) Antibody Basic Information
Table 120. OriGene Technologies CD30 (TNFRSF8) Antibody Product Overview
Table 121. OriGene Technologies CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 122. OriGene Technologies Business Overview
Table 123. OriGene Technologies Recent Developments
Table 124. Inc. CD30 (TNFRSF8) Antibody Basic Information
Table 125. Inc. CD30 (TNFRSF8) Antibody Product Overview
Table 126. Inc. CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 127. Inc. Business Overview
Table 128. Inc. Recent Developments
Table 129. Merck CD30 (TNFRSF8) Antibody Basic Information
Table 130. Merck CD30 (TNFRSF8) Antibody Product Overview
Table 131. Merck CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 132. Merck Business Overview
Table 133. Merck Recent Developments
Table 134. Cayman Chemical CD30 (TNFRSF8) Antibody Basic Information
Table 135. Cayman Chemical CD30 (TNFRSF8) Antibody Product Overview
Table 136. Cayman Chemical CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 137. Cayman Chemical Business Overview
Table 138. Cayman Chemical Recent Developments
Table 139. CUSABIO CD30 (TNFRSF8) Antibody Basic Information
Table 140. CUSABIO CD30 (TNFRSF8) Antibody Product Overview
Table 141. CUSABIO CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 142. CUSABIO Business Overview
Table 143. CUSABIO Recent Developments
Table 144. Biotium CD30 (TNFRSF8) Antibody Basic Information
Table 145. Biotium CD30 (TNFRSF8) Antibody Product Overview
Table 146. Biotium CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 147. Biotium Business Overview
Table 148. Biotium Recent Developments
Table 149. BioLegend CD30 (TNFRSF8) Antibody Basic Information
Table 150. BioLegend CD30 (TNFRSF8) Antibody Product Overview
Table 151. BioLegend CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 152. BioLegend Business Overview
Table 153. BioLegend Recent Developments
Table 154. Abcepta CD30 (TNFRSF8) Antibody Basic Information
Table 155. Abcepta CD30 (TNFRSF8) Antibody Product Overview
Table 156. Abcepta CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 157. Abcepta Business Overview
Table 158. Abcepta Recent Developments
Table 159. ProSci Incorporated CD30 (TNFRSF8) Antibody Basic Information
Table 160. ProSci Incorporated CD30 (TNFRSF8) Antibody Product Overview
Table 161. ProSci Incorporated CD30 (TNFRSF8) Antibody Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 162. ProSci Incorporated Business Overview
Table 163. ProSci Incorporated Recent Developments
Table 164. Global CD30 (TNFRSF8) Antibody Sales Forecast by Region (2025-2032) & (K MT)
Table 165. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Region (2025-2032) & (M USD)
Table 166. North America CD30 (TNFRSF8) Antibody Sales Forecast by Country (2025-2032) & (K MT)
Table 167. North America CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2025-2032) & (M USD)
Table 168. Europe CD30 (TNFRSF8) Antibody Sales Forecast by Country (2025-2032) & (K MT)
Table 169. Europe CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2025-2032) & (M USD)
Table 170. Asia Pacific CD30 (TNFRSF8) Antibody Sales Forecast by Region (2025-2032) & (K MT)
Table 171. Asia Pacific CD30 (TNFRSF8) Antibody Market Size Forecast by Region (2025-2032) & (M USD)
Table 172. South America CD30 (TNFRSF8) Antibody Sales Forecast by Country (2025-2032) & (K MT)
Table 173. South America CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2025-2032) & (M USD)
Table 174. Middle East and Africa CD30 (TNFRSF8) Antibody Consumption Forecast by Country (2025-2032) & (Units)
Table 175. Middle East and Africa CD30 (TNFRSF8) Antibody Market Size Forecast by Country (2025-2032) & (M USD)
Table 176. Global CD30 (TNFRSF8) Antibody Sales Forecast by Type (2025-2032) & (K MT)
Table 177. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Type (2025-2032) & (M USD)
Table 178. Global CD30 (TNFRSF8) Antibody Price Forecast by Type (2025-2032) & (USD/MT)
Table 179. Global CD30 (TNFRSF8) Antibody Sales (K MT) Forecast by Application (2025-2032)
Table 180. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Application (2025-2032) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of CD30 (TNFRSF8) Antibody
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global CD30 (TNFRSF8) Antibody Market Size (M USD), 2019-2032
Figure 5. Global CD30 (TNFRSF8) Antibody Market Size (M USD) (2019-2032)
Figure 6. Global CD30 (TNFRSF8) Antibody Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. CD30 (TNFRSF8) Antibody Market Size by Country (M USD)
Figure 11. CD30 (TNFRSF8) Antibody Sales Share by Manufacturers in 2023
Figure 12. Global CD30 (TNFRSF8) Antibody Revenue Share by Manufacturers in 2023
Figure 13. CD30 (TNFRSF8) Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market CD30 (TNFRSF8) Antibody Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by CD30 (TNFRSF8) Antibody Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global CD30 (TNFRSF8) Antibody Market Share by Type
Figure 18. Sales Market Share of CD30 (TNFRSF8) Antibody by Type (2019-2024)
Figure 19. Sales Market Share of CD30 (TNFRSF8) Antibody by Type in 2023
Figure 20. Market Size Share of CD30 (TNFRSF8) Antibody by Type (2019-2024)
Figure 21. Market Size Market Share of CD30 (TNFRSF8) Antibody by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global CD30 (TNFRSF8) Antibody Market Share by Application
Figure 24. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2019-2024)
Figure 25. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application in 2023
Figure 26. Global CD30 (TNFRSF8) Antibody Market Share by Application (2019-2024)
Figure 27. Global CD30 (TNFRSF8) Antibody Market Share by Application in 2023
Figure 28. Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2019-2024)
Figure 29. Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2019-2024)
Figure 30. North America CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 31. North America CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2023
Figure 32. U.S. CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 33. Canada CD30 (TNFRSF8) Antibody Sales (K MT) and Growth Rate (2019-2024)
Figure 34. Mexico CD30 (TNFRSF8) Antibody Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 36. Europe CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2023
Figure 37. Germany CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 38. France CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 39. U.K. CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 40. Italy CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 41. Russia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 42. Asia Pacific CD30 (TNFRSF8) Antibody Sales and Growth Rate (K MT)
Figure 43. Asia Pacific CD30 (TNFRSF8) Antibody Sales Market Share by Region in 2023
Figure 44. China CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 45. Japan CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 46. South Korea CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 47. India CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 48. Southeast Asia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 49. South America CD30 (TNFRSF8) Antibody Sales and Growth Rate (K MT)
Figure 50. South America CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2023
Figure 51. Brazil CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 52. Argentina CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 53. Columbia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 54. Middle East and Africa CD30 (TNFRSF8) Antibody Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa CD30 (TNFRSF8) Antibody Sales Market Share by Region in 2023
Figure 56. Saudi Arabia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 57. UAE CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 58. Egypt CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 59. Nigeria CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 60. South Africa CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 61. Global CD30 (TNFRSF8) Antibody Production Market Share by Region (2019-2024)
Figure 62. North America CD30 (TNFRSF8) Antibody Production (K MT) Growth Rate (2019-2024)
Figure 63. Europe CD30 (TNFRSF8) Antibody Production (K MT) Growth Rate (2019-2024)
Figure 64. Japan CD30 (TNFRSF8) Antibody Production (K MT) Growth Rate (2019-2024)
Figure 65. China CD30 (TNFRSF8) Antibody Production (K MT) Growth Rate (2019-2024)
Figure 66. Global CD30 (TNFRSF8) Antibody Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global CD30 (TNFRSF8) Antibody Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global CD30 (TNFRSF8) Antibody Market Share Forecast by Type (2025-2032)
Figure 70. Global CD30 (TNFRSF8) Antibody Sales Forecast by Application (2025-2032)
Figure 71. Global CD30 (TNFRSF8) Antibody Market Share Forecast by Application (2025-2032)
Figure 1. Product Picture of CD30 (TNFRSF8) Antibody
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global CD30 (TNFRSF8) Antibody Market Size (M USD), 2019-2032
Figure 5. Global CD30 (TNFRSF8) Antibody Market Size (M USD) (2019-2032)
Figure 6. Global CD30 (TNFRSF8) Antibody Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. CD30 (TNFRSF8) Antibody Market Size by Country (M USD)
Figure 11. CD30 (TNFRSF8) Antibody Sales Share by Manufacturers in 2023
Figure 12. Global CD30 (TNFRSF8) Antibody Revenue Share by Manufacturers in 2023
Figure 13. CD30 (TNFRSF8) Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market CD30 (TNFRSF8) Antibody Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by CD30 (TNFRSF8) Antibody Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global CD30 (TNFRSF8) Antibody Market Share by Type
Figure 18. Sales Market Share of CD30 (TNFRSF8) Antibody by Type (2019-2024)
Figure 19. Sales Market Share of CD30 (TNFRSF8) Antibody by Type in 2023
Figure 20. Market Size Share of CD30 (TNFRSF8) Antibody by Type (2019-2024)
Figure 21. Market Size Market Share of CD30 (TNFRSF8) Antibody by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global CD30 (TNFRSF8) Antibody Market Share by Application
Figure 24. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2019-2024)
Figure 25. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application in 2023
Figure 26. Global CD30 (TNFRSF8) Antibody Market Share by Application (2019-2024)
Figure 27. Global CD30 (TNFRSF8) Antibody Market Share by Application in 2023
Figure 28. Global CD30 (TNFRSF8) Antibody Sales Growth Rate by Application (2019-2024)
Figure 29. Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2019-2024)
Figure 30. North America CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 31. North America CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2023
Figure 32. U.S. CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 33. Canada CD30 (TNFRSF8) Antibody Sales (K MT) and Growth Rate (2019-2024)
Figure 34. Mexico CD30 (TNFRSF8) Antibody Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 36. Europe CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2023
Figure 37. Germany CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 38. France CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 39. U.K. CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 40. Italy CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 41. Russia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 42. Asia Pacific CD30 (TNFRSF8) Antibody Sales and Growth Rate (K MT)
Figure 43. Asia Pacific CD30 (TNFRSF8) Antibody Sales Market Share by Region in 2023
Figure 44. China CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 45. Japan CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 46. South Korea CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 47. India CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 48. Southeast Asia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 49. South America CD30 (TNFRSF8) Antibody Sales and Growth Rate (K MT)
Figure 50. South America CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2023
Figure 51. Brazil CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 52. Argentina CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 53. Columbia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 54. Middle East and Africa CD30 (TNFRSF8) Antibody Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa CD30 (TNFRSF8) Antibody Sales Market Share by Region in 2023
Figure 56. Saudi Arabia CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 57. UAE CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 58. Egypt CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 59. Nigeria CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 60. South Africa CD30 (TNFRSF8) Antibody Sales and Growth Rate (2019-2024) & (K MT)
Figure 61. Global CD30 (TNFRSF8) Antibody Production Market Share by Region (2019-2024)
Figure 62. North America CD30 (TNFRSF8) Antibody Production (K MT) Growth Rate (2019-2024)
Figure 63. Europe CD30 (TNFRSF8) Antibody Production (K MT) Growth Rate (2019-2024)
Figure 64. Japan CD30 (TNFRSF8) Antibody Production (K MT) Growth Rate (2019-2024)
Figure 65. China CD30 (TNFRSF8) Antibody Production (K MT) Growth Rate (2019-2024)
Figure 66. Global CD30 (TNFRSF8) Antibody Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global CD30 (TNFRSF8) Antibody Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global CD30 (TNFRSF8) Antibody Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global CD30 (TNFRSF8) Antibody Market Share Forecast by Type (2025-2032)
Figure 70. Global CD30 (TNFRSF8) Antibody Sales Forecast by Application (2025-2032)
Figure 71. Global CD30 (TNFRSF8) Antibody Market Share Forecast by Application (2025-2032)
